CJC-1295 side effects: what studies and regulators have recorded

What are the side effects of CJC-1295?

In two randomised, double-blind trials lasting 28 and 49 days, healthy adults aged 21 to 61 received CJC-1295 or placebo, and the authors reported no serious adverse reactions and concluded the peptide was safe and relatively well tolerated; the abstract gives no participant count, names no specific mild effects and gives no event counts (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006).

The record is thinner than most pages admit. The full 2006 paper sits behind a journal paywall and was not available for this page, so each statement here rests on its abstract and on later reviews. A second human paper followed healthy men for one week after one exposure and reported hormone results, not a safety table, and its abstract gives no participant count (Ionescu and Frohman, Journal of Clinical Endocrinology & Metabolism, 2006). None of the abstracts and reviews read for this page gives a percentage of participants with a named effect such as headache or flushing.

Class-wide reviews list effects across the whole family of growth hormone-axis peptides, not CJC-1295 alone. The 2026 review names prolactin and cortisol rises, appetite change, blood-sugar change, fluid retention, muscle and joint aches, and reactions at the site where the drug was given, as a class list from a narrative review and not a measurement for CJC-1295 (Dominikowski et al., 2026). It ties the prolactin and cortisol rises to older ghrelin-mimetic peptides such as GHRP-2, GHRP-6 and hexarelin, and describes ipamorelin and the GHRH analogues as sparing, again as a review's reading of other work. A class list shows what researchers watch for.

Evidence limits

Is CJC-1295 safe?

The registry record gives no reason for the termination, so none is assumed here. It describes a multicentre, randomised, placebo-controlled, double-blind phase 2 study with a planned study period of 12 weeks plus 6 weeks of follow-up in HIV-infected adults with visceral obesity. Its status was last verified in October 2006. No results paper appears among the titles of the 59 records returned by a Europe PMC search for CJC-1295 on 14 October 2026.

A 2026 review of peptide therapies in sports medicine states that favourable results in animal models exist for many unapproved peptides, that rigorous human safety data on them are scarce and that serious harm is possible; this is a statement about the group and not a finding on CJC-1295 (Mendias and Awan, Sports Medicine, 2026). Safe-until-proven-otherwise is not a standard anyone applies to medicines.

What does the FDA say about CJC-1295 safety?

The FDA lists serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, meaning a widening of blood vessels throughout the body. The agency adds that available clinical data are limited, and the page does not name the study or report behind the events. It also says compounded drugs containing CJC-1295 may carry a risk of immunogenicity (the body making antibodies to the peptide) for certain routes and may raise impurity and characterisation problems (FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 22 April 2026).

Read the page closely and one more limit appears. CJC-1295 sits on the page's list of substances whose compounding nominations were withdrawn, not on its category 2 table of active safety concerns.

The same page lists ipamorelin acetate in category 2 for outsourcing facilities (section 503B of the US Federal Food, Drug, and Cosmetic Act), added 29 September 2023. The FDA cites unnatural amino acids that complicate characterisation, and a published study that identified serious adverse events including death in ipamorelin used for gastric motility. The page does not name that study in its text, but its linked reference is Beck et al. (2014), PubMed 25331030; the FDA's report and that paper's separately checked results are kept apart on this page, and no death count or cause is inferred from the abstract. The agency says it has found no safety information for certain other routes. This is a US compounding rule, not Australian law. The Australian law guide covers the Poisons Standard.

What are the side effects of CJC-1295 with DAC?

CJC-1295 with DAC is the only form with published human safety data found for this page: in two randomised trials of healthy adults aged 21 to 61, with no participant count in the abstract, the authors reported no serious adverse reactions (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). DAC, the drug affinity complex, is a chemical hook that bonds the peptide to albumin, a protein carried in the blood. In two trials of healthy adults aged 21 to 61 lasting 28 and 49 days, with no participant count in the abstract, the estimated half-life was 5.8 to 8.1 days, and mean IGF-I levels, a growth hormone-driven marker, stayed above baseline for up to 28 days after repeated exposures; these are hormone-level results with no event counts in the abstract (Teichman et al., 2006). What DAC is and is not is covered separately.

A long half-life changes what researchers worry about. Growth hormone makes the liver produce IGF-I (insulin-like growth factor I), a growth signal. A 2026 narrative review describes chronic IGF-I elevation as the central long-term concern for the whole class, along with biologically plausible but unproven mitogenic effects, meaning effects that could encourage cell growth, and rests this on class-wide reasoning and not on CJC-1295 trial data (Dominikowski et al., 2026). For the approved analogue tesamorelin, the US label states that the effects of prolonged IGF-1 elevation are unknown (Egrifta SV label, DailyMed, effective 29 July 2026). No study found measured these questions for CJC-1295 over months or years.

The CJC-1295 with DAC versus without DAC guide sets out how the two forms differ in structure and in the published record.

What are the side effects of CJC-1295 without DAC?

Dominikowski et al. (Frontiers in Endocrinology, 2026) report finding no peer-reviewed human studies of CJC-1295 without DAC; that review finding does not establish whether adverse effects have been recorded elsewhere. The review places the form in the lowest of four evidence tiers, supported only by preclinical extrapolation and user narratives, which is a tier assignment and not a safety finding (Dominikowski et al., 2026). The review adds that claims about the form come largely from related compounds such as sermorelin, the unmodified fragment, and from non-academic sources. The safety of the form is unknown.

Teichman's human data belong to the DAC form, so they cannot be borrowed for the shorter peptide. The two molecules differ in length, half-life and registry record. The form comparison guide reports a PubMed search on 3 October 2026 that found no measured human half-life for the without-DAC peptide.

What are the side effects of CJC-1295 with ipamorelin?

No published human safety study of CJC-1295 and ipamorelin together was found. A Europe PMC search on 14 October 2026 found 22 records that mention both names, and by title none reports a controlled human trial of the pair; they are reviews, preprints, doping-analysis papers, product-quality evaluations and surveys. The 2026 narrative review in Frontiers in Endocrinology calls controlled evidence for the pairing limited (Dominikowski et al., 2026). Ipamorelin alone has one phase 2 trial, a small proof-of-concept study that enrolled 117 patients after bowel surgery, 114 of them analysed for safety, in which any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group; the authors note it enrolled patients with a broad range of conditions (Beck et al., International Journal of Colorectal Disease, 2014).

The Beck authors concluded that ipamorelin was well tolerated over its short in-hospital treatment period and did not differ from placebo on the main efficacy measure, in 114 analysed surgery patients in a small proof-of-concept trial (Beck et al., 2014). That is a hospital trial in patients after surgery, with a different purpose, and it says little about any other group or about two peptides together. The trial is registered as NCT00672074, and a second ileus trial, NCT01280344, lists 320 participants and no posted results (ClinicalTrials.gov, checked 14 October 2026).

In conscious pigs, ACTH and cortisol levels after ipamorelin were not significantly different from those after GHRH stimulation, whereas GHRP-6 and GHRP-2 raised them; this is an animal result that describes selectivity and not safety in people (Raun et al., European Journal of Endocrinology, 1998).

What are the long-term side effects of CJC-1295?

The long-term side effects of CJC-1295 are unknown, because no long-term human study was found. The longest published human trials found ran 28 and 49 days in healthy adults, with no participant count in the abstract (Teichman et al., 2006), and a 2026 narrative review states that no long-term safety data are available for the DAC form (Dominikowski et al., 2026). Sport Integrity Australia, on its peptides page read on 14 October 2026, says few studies examine the long-term health effects of unapproved peptides, so potential side effects remain largely unknown, and that most toxicity research is in animal models.

Compare that with an approved relative. The US label for tesamorelin, which rests on trials in patients, states that long-term cardiovascular safety has not been established (Egrifta SV label, DailyMed, effective 29 July 2026). The two Teichman trials followed healthy adults for 28 and 49 days, with no participant count in the abstract; those trials cannot establish long-term safety (Teichman et al., 2006).

What side effects does the label of tesamorelin, an approved GHRH analogue, list?

Tesamorelin (Egrifta), a different GHRH analogue approved in the United States for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, lists as its most commonly reported adverse reactions hypersensitivity reactions, oedema-related reactions (arthralgia, extremity pain, peripheral oedema and carpal tunnel syndrome), hyperglycaemia and reactions at the site where the drug was given, among 543 patients who received it in the 26-week placebo-controlled phase of its trials (Egrifta SV label, DailyMed, effective 29 July 2026). The label's warnings cover neoplasms, raised IGF-1, fluid retention, glucose intolerance and hypersensitivity (same label). These entries describe tesamorelin in patients with HIV. They are not measurements for CJC-1295, and they do not make any research material equivalent to the approved medicine.

The label gives counts that CJC-1295 lacks. Its glucose-intolerance warning comes from the same trials, and the passage read gives no denominator for its HbA1c figures, so this page does not repeat them (Egrifta WR label, DailyMed, effective 29 July 2026). In the pivotal trial of 412 adults with HIV over 26 weeks, adverse events did not differ significantly between groups, though more tesamorelin patients withdrew because of one; the result belongs to that medicine in that population (Falutz et al., New England Journal of Medicine, 2007).

Why mention a different molecule? Because it shows the shape of the missing evidence. A regulated growth hormone-releasing analogue has trial tables and warnings. CJC-1295 has two short trials in the records read and a terminated one.

What adverse events has the TGA recorded for unapproved peptide products?

The Therapeutic Goods Administration (TGA) safety advisory of 13 April 2026 lists reports linked to unapproved peptide products as a group: severe allergic reactions needing adrenaline and hospital care, systemic inflammatory response syndrome, generalised hypersensitivity symptoms, insomnia, blurred vision, extreme tiredness, flu-like illness, joint pain and musculoskeletal injuries (TGA advisory). The advisory names CJC-1295 as an example of an unapproved peptide product and does not attribute any single report to CJC-1295. Because the events are listed for the group, they show what regulators see in practice, not how often any one peptide causes them.

The TGA also says unapproved peptide products have not been assessed for safety, quality or effectiveness, and that important information is unknown, including what side effects they may cause and what the products contain. It adds that a research-use-only label does not make supply lawful and does not change a product's regulatory status. The Australian law guide sets out the Poisons Standard entries for CJC-1295.

What do anti-doping bodies say about CJC-1295?

The World Anti-Doping Agency (WADA) Prohibited List 2026, in effect from 1 January 2026, names CJC-1295 as an example of a growth hormone-releasing hormone analogue under S2.2.4, in the class prohibited at all times. Sport Integrity Australia lists CJC-1295 among common unapproved peptides prohibited in sport and says athletes risk anti-doping rule violations and bans (Sport Integrity Australia, peptides page, read 14 October 2026). Both documents record sport status. Neither is a safety trial, and neither reports an adverse-event rate for CJC-1295.

The Sport Integrity Australia page also says unapproved peptides do not pass the same quality control as approved medicines, so purity and composition can vary widely, which could lead to serious harm. It points to the TGA's reported effects of severe allergic reactions, inflammation, blurred vision, extreme tiredness and musculoskeletal injuries. Those are the TGA's class-wide reports, not a CJC-1295 finding.

Is research-use CJC-1295 the material the studies tested?

No. The studies above tested the sponsor's trial product, given to enrolled participants under clinical-trial conditions (Teichman et al., 2006). Research-use reference material is a laboratory compound. Its published safety record is the record described on this page, and none of it describes any material outside those trials. A certificate of analysis describes one sample and one lot, so it cannot carry a trial's safety record across. Research material is not a medicine, is not a substitute for one, and is not for human or animal use.

The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial, with the split between the two compounds unstated. Most of the human safety record above concerns the DAC form, so it is background for naming and method, not direct evidence about the No DAC peptide. The CJC-1295 and ipamorelin research guide covers the compound families.